Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia Patients

View ORCID ProfileNestoras Karathanasis, Panayiota Papasavva, Anastasis Oulas, View ORCID ProfileGeorge M Spyrou
doi: https://doi.org/10.1101/2024.02.29.24303536
Nestoras Karathanasis
1Bioinformatics Department, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nestoras Karathanasis
  • For correspondence: nestorask{at}cing.ac.cy
Panayiota Papasavva
2Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasis Oulas
1Bioinformatics Department, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George M Spyrou
1Bioinformatics Department, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for George M Spyrou
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background and Objective The standard of care in Acute Myeloid Leukemia patients has remained essentially unchanged for nearly 40 years. Due to the complicated mutational patterns within and between individual patients and a lack of targeted agents for most mutational events, implementing individualized treatment for AML has proven difficult. We reanalysed the BeatAML dataset employing Machine Learning algorithms. The BeatAML project entails patients extensively characterized at the molecular and clinical levels and linked to drug sensitivity outputs. Our approach capitalizes on the molecular and clinical data provided by the BeatAML dataset to predict the ex vivo drug sensitivity for the 122 drugs evaluated by the project.

Methods We utilized ElasticNet, which produces fully interpretable models, in combination with a two-step training protocol that allowed us to narrow down computations. We automated the genes’ filtering step by employing two metrics, and we evaluated all possible data combinations to identify the best training configuration settings per drug.

Results We report a Pearson correlation across all drugs of 0.36 when clinical and RNA sequencing data were combined, with the best-performing models reaching a Pearson correlation of 0.67. When we trained using the datasets in isolation, we noted that RNA Sequencing data (Pearson: 0.36) attained three times the predictive power of whole exome sequencing data (Pearson: 0.11), with clinical data falling somewhere in between (Pearson 0.26). Lastly, we present a paradigm of clinical significance. We used our models’ prediction as a health management score to rank an individual’s expected response to treatment. We identified 78 patients out of 89 (88%) that the proposed drug was more potent than the administered one based on their ex vivo drug sensitivity data.

Conclusions In conclusion, our reanalysis of the BeatAML dataset using Machine Learning algorithms demonstrates the potential for individualized treatment prediction in Acute Myeloid Leukemia patients, addressing the longstanding challenge of treatment personalization in this disease. By leveraging molecular and clinical data, our approach yields promising correlations between predicted drug sensitivity and actual responses, highlighting a significant step forward in improving therapeutic outcomes for AML patients.

Highlights

  • Machine learning can predict response to treatment in Acute Myeloid Leukemia patients.

  • RNA sequencing data are more informative than whole exome sequencing and clinical data in predicting drug response in Acute Myeloid Leukemia patients.

  • Drug response predictions could be used as a health management score to rank the individual’s expected response to treatment.

  • We identified a more potent drug than the administered one for 88% (78 out of 89) of the patients examined.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below: the supplementary material of the initial publication, https://www.nature.com/articles/s41586-018-0623-z, under the section "Supplementary Tables" and can be found here: https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-018-0623-z/MediaObjects/41586_2018_623_MOESM3_ESM.xlsx

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced are available online at the supplementary material of the initial publication: https://www.nature.com/articles/s41586-018-0623-z, under the section "Supplementary Tables" and can be found here: https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-018-0623-z/MediaObjects/41586_2018_623_MOESM3_ESM.xlsx

https://www.nature.com/articles/s41586-018-0623-z

  • Abbreviations

    (AML)
    Acute Myeloid Leukemia
    (AlloSCT)
    Allogeneic Stem Cell Transplantation
    (HMAs)
    hypomethylating agents
    (AUC)
    Area Under the dose-response Curve
    (TCGA)
    The Cancer Genome Atlas
    (TARGET)
    Therapeutically Applicable Research to Generate Effective Treatments
    (LASSO)
    regularized regression modelling
    (DRUML)
    Drug Ranking Using ML
    (CPM)
    Counts Per Million
    (RPKM)
    Read Per Kilobase Million
    (MSE)
    the Mean Square Error
    (auc_hat)
    AUC prediction
    (cvMSE)
    cross validated MSE
    (nestedcvMSE)
    nested cross-validation
    (mean_nestedcvMSE)
    mean nestedcvMSE
    (mean_pearson)
    mean Pearson
    (mean_spearman)
    mean Spearman
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted March 02, 2024.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia Patients
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia Patients
    Nestoras Karathanasis, Panayiota Papasavva, Anastasis Oulas, George M Spyrou
    medRxiv 2024.02.29.24303536; doi: https://doi.org/10.1101/2024.02.29.24303536
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia Patients
    Nestoras Karathanasis, Panayiota Papasavva, Anastasis Oulas, George M Spyrou
    medRxiv 2024.02.29.24303536; doi: https://doi.org/10.1101/2024.02.29.24303536

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Genetic and Genomic Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)